| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 500 | 2020 |
| Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia P Blombery, MA Anderson, J Gong, R Thijssen, RW Birkinshaw, ... Cancer discovery 9 (3), 342-353, 2019 | 401 | 2019 |
| Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations RW Birkinshaw, J Gong, CS Luo, D Lio, CA White, MA Anderson, ... Nature communications 10 (1), 2385, 2019 | 185 | 2019 |
| IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells MF Pascutti, M Jak, JM Tromp, IAM Derks, EBM Remmerswaal, ... Blood, The Journal of the American Society of Hematology 122 (17), 3010-3019, 2013 | 179 | 2013 |
| Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma R Agarwal, YC Chan, CS Tam, T Hunter, D Vassiliadis, CE Teh, ... Nature medicine 25 (1), 119-129, 2019 | 173 | 2019 |
| Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors R Thijssen, E Slinger, K Weller, CR Geest, T Beaumont, MHJ Van Oers, ... Haematologica 100 (8), e302, 2015 | 157 | 2015 |
| Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax P Blombery, ER Thompson, T Nguyen, RW Birkinshaw, J Gong, X Chen, ... Blood, The Journal of the American Society of Hematology 135 (10), 773-777, 2020 | 141 | 2020 |
| Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing L Tian, JS Jabbari, R Thijssen, Q Gouil, SL Amarasinghe, O Voogd, ... Genome biology 22, 1-24, 2021 | 129 | 2021 |
| Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy MFM de Rooij, A Kuil, AP Kater, MJ Kersten, ST Pals, M Spaargaren Blood, The Journal of the American Society of Hematology 125 (14), 2306-2309, 2015 | 105 | 2015 |
| Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias R Thijssen, ST Diepstraten, D Moujalled, E Chew, C Flensburg, MX Shi, ... Blood, The Journal of the American Society of Hematology 137 (20), 2721-2735, 2021 | 98 | 2021 |
| Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia R Thijssen, J Ter Burg, B Garrick, GGW van Bochove, JR Brown, ... Blood, The Journal of the American Society of Hematology 128 (4), 574-583, 2016 | 86 | 2016 |
| Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL M Haselager, R Thijssen, C West, L Young, R Van Kampen, E Willmore, ... Cell Death & Differentiation 28 (5), 1658-1668, 2021 | 59 | 2021 |
| Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy R Thijssen, L Tian, MA Anderson, C Flensburg, A Jarratt, AL Garnham, ... Blood, The Journal of the American Society of Hematology 140 (20), 2127-2141, 2022 | 52 | 2022 |
| Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition E Slinger, R Thijssen, AP Kater, E Eldering Leukemia 31 (12), 2601-2607, 2017 | 43 | 2017 |
| CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex C Maas, JM Tromp, J Van Laar, R Thijssen, JA Elias, A Malara, ... Cell Death & Disease 4 (8), e782-e782, 2013 | 39 | 2013 |
| The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic … R Thijssen, J Ter Burg, GGW Van Bochove, MFM De Rooij, A Kuil, ... Leukemia 30 (2), 337-345, 2016 | 26 | 2016 |
| Venetoclax in lymphoid malignancies: new insights, more to learn R Thijssen, AW Roberts Cancer Cell 36 (4), 341-343, 2019 | 25 | 2019 |
| Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors ER Thompson, T Nguyen, Y Kankanige, JF Markham, MA Anderson, ... Blood advances 6 (2), 503-508, 2022 | 23 | 2022 |
| Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma MA Dengler, CE Teh, R Thijssen, L Gangoda, P Lan, MJ Herold, DH Gray, ... Oncogene 39 (9), 2009-2023, 2020 | 21 | 2020 |
| Bh3 mimetics for the treatment of b-cell malignancies—insights and lessons from the clinic VS Lin, ZF Xu, DCS Huang, R Thijssen Cancers 12 (11), 3353, 2020 | 17 | 2020 |
